{"text_format":"2","workbook":"xls","n_sheets":1,"sheets":["report2"],"not_rendered":{"charts":0,"images":0,"macros":0,"external_links":1,"defined_names":1,"comments":0,"pivot_tables":0},"unopened":[],"bounds":{"document_bytes":16777216,"sheet_cells":100000,"run_cost":"one","rows_first":2000,"rows_last":500,"rows_between":2000,"halvings":0,"cell_chars":16384,"cell_head_chars":4096},"cells_cut":0,"cells_raw":0,"read":"whole","date_system":"1900","formulas":"cached_only"}

{"sheet":"report2","index":0,"n_rows":21,"n_cols":5,"rows_kept":21,"cut":false,"hidden":false,"merged":[[0,2,0,3],[0,4,0,5],[1,2,1,3],[1,4,1,5],[2,2,2,3],[3,2,3,3],[4,2,4,3],[5,2,5,3],[6,2,6,3],[9,2,9,3],[10,2,10,3],[14,2,14,3]],"flags":["formulas_cached_only"]}
[null,"1.","Record Nr.",null,"UNINA9910452895703321"]
[null,null,"Titolo",null,"Acute rejection [[electronic resource] ] : risk factors, management and complications / / Takumi Kobayashi, Riku Arai, editors"]
[null,null,"Pubbl/distr/stampa",null,"Hauppauge, NY, : Nova Science Publishers, Inc., 2012"]
[null,null,"ISBN",null,"1-61942-351-0"]
[null,null,"Descrizione fisica",null,"1 online resource (211 p.)"]
[null,null,"Collana",null,"Immunology and immune system disorders"]
[null,null,"Soggetti",null,"Graft rejection"]
[{"$nulls":4},"Transplantation immunology"]
[{"$nulls":4},"Electronic books."]
[null,null,"Lingua di pubblicazione",null,"Inglese"]
[null,null,"Formato",null,"Materiale a stampa"]
[null,null,null,"Livello bibliografico","Monografia"]
[null,null,null,"Note generali","Description based upon print version of record."]
[null,null,null,"Nota di bibliografia","Includes bibliographical references and index."]
[null,null,"Nota di contenuto",null,"\"\"ACUTE REJECTION: RISK FACTORS, MANAGEMENT AND COMPLICATIONS\"\"; \"\"ACUTE REJECTION: RISK FACTORS, MANAGEMENT AND COMPLICATIONS\"\"; \"\"Library of Congress Cataloging-in-Publication Data\"\"; \"\"Contents\"\"; \"\"Preface\"\"; \"\"Chapter 1: HLA and Non-HLA Genes Polymorphisms: Susceptibility  and Severity in Tunisian Patients  with Rheumatoid Arthritis\"\"; \"\"Abstract\"\"; \"\"1. Introduction\"\"; \"\"2. Evaluation of Genetic Predisposition to RA\"\"; \"\"2.1. Prevalence of RA\"\"; \"\"2.2. Familial Clustering Studies\"\"; \"\"2.3. Twins Studies\"\"; \"\"3. Identification of Candidate Genes\"\"; \"\"3.1. Linkage Studies\"\""]
[{"$nulls":4},"\"\"3.2. Candidate Gene Association Studies\"\"\"\"4. Results of Linkage Studies in RA\"\"; \"\"5. HLA Association With RA\"\"; \"\"6. Non HLA Candidate Genes  Case-control Studies\"\"; \"\"6.1. Protein Tyrosine Phosphatase Non-Receptor, Type 22 (PTPN22)\"\"; \"\"6.2. Tumor Necrosis Factor Receptor Type 2 (TNF-R2)\"\"; \"\"6.3. Peptidyl Arginine Deiminase 4 (PADI 4)\"\"; \"\"6.4. Fc Î³ Receptor IIIa (FcÎ³RIIIa)\"\"; \"\"6.5. Interleukin 1 Receptor Antagonist (IL-1Ra)\"\"; \"\"6.6. Cytotoxic T Lymphocyte-Associated Antigen-4 (CTLA-4)\"\"; \"\"6.7. Apo-1/Fas (CD95)\"\"; \"\"6.8. Adhesion Molecules\"\"; \"\"7. Patients and Methods\"\""]
[{"$nulls":4},"\"\"7.1. Patients and Controls\"\"\"\"7.2. Methods\"\"; \"\"7.3. Statistical Methods\"\"; \"\"8. Results\"\"; \"\"8.1. HLA Typing\"\"; \"\"a/ DRB1 Genotyping\"\"; \"\"b/ DRB1*04 Sub-typing\"\"; \"\"8.2. PTPN22 Genotyping\"\"; \"\"8.3. CTLA-4 Genotyping\"\"; \"\"8.4. Apo-1/Fas Genotyping\"\"; \"\"8.5. FcÎ³R Genotyping\"\"; \"\"8.6. Adhesion Molecules Genotyping\"\"; \"\"8.7. IL1 Family Polymorphisms Genotyping\"\"; \"\"a/ IL1Î± (C/T -889)\"\"; \"\"b/ IL1Ra (Intron 2)\"\"; \"\"c/ IL1Î² C/T -511 and C/T +3954\"\"; \"\"9. Discussion\"\"; "]
[{"$nulls":4},"\"\"Conclusion\"\"; \"\"Acknowledgment\"\"; \"\"References\"\""]
[{"$nulls":4},"\"\"Chapter 2: Mechanisms, Management  and Consequences of Acute  Cellular and Antibody Mediated Rejection in Solid Organ and Reconstructive Transplantation\"\"\"\"Abstract\"\"; \"\"1. Acute Rejection\"\"; \"\"2. Kidney Transplantation\"\"; \"\"2.1 The Banff Classification\"\"; \"\"2.2 Acute Antibody-Mediated Rejection in Kidney Transplantation\"\"; \"\"2.3 Acute T-Cell-Mediated Rejection in Kidney Transplantation\"\"; \"\"2.3.1. Steps in TCMR â€? 3 Signals [12]\"\"; \"\"3. Pancreas Transplantation\"\"; \"\"3.1 The Banff Classification\"\"; \"\"3.2 Acute Antibody-Mediated Rejection in Pancreas Transplantation\"\""]
[{"$nulls":4},"\"\"3.3 Acute T-Cell-Mediated Rejection in Pancreas Transplantation\"\"\"\"4. Liver Transplantation\"\"; \"\"4.1 Banff Schema for Grading of Liver Allograft Rejection\"\"; \"\"4.2 Acute Antibody-Mediated Rejection in Liver Transplantation\"\"; \"\"4.3 Acute T-Cell-Mediated Rejection in Liver Transplantation\"\"; \"\"5. Intestinal and Multivisceral Transplantation\"\"; \"\"5.2 Acute Antibody-Mediated Rejection  in Intestinal Transplantation\"\"; \"\"5.3 Acute T-Cell-Mediated Rejection  in Intestinal Transplantation\"\"; \"\"6. Vascularized Composite Allotransplantation\"\""]
[{"$nulls":4},"\"\"6.1 Banff Classification of Skin-Containing Composite  Tissue Allografts\"\""]